A recent report published by Infinium Global Research on bio
simulation market provides an in-depth analysis of segments and sub-segments in
the global as well as regional bio simulation market. The study also highlights
the impact of drivers, restraints, and macro indicators on the global and
regional bio simulation market over the short term as well as long term. The
report is a comprehensive presentation of trends, forecast and dollar values of the global bio simulation market. According to the report, the global bio
simulation market is projected to grow at a CAGR of 16.5% over the forecast
period of 2020-2026.
Market Insight
Bio simulation is an advanced technology used for the
simulation of biological processes through computer programming. Bio simulation
provides a defined approach for integrating the clinical and biological data
into effective metabolic pathways and has a wide range of applications such as
obtaining a quantitative understanding of regulation of blood levels and
glucose simulated insulin secretion in order to investigate the role the
various physiological processes play in diabetes and others. Bio simulation finds
wide range of application in target identification & validation, lead
discovery & optimization, preclinical testing and clinical trials. The
current concerns over the spread of coronavirus infection are creating a major
demand for bio simulation in the global market.
The impact of the COVID 19 pandemic on bio simulation market
is expected to be noteworthy as more countries resort to continuous research to
control the spread of the disease. Global health care facilities have become
overburdened with potentially infectious patients seeking testing and care.
Furthermore, as preventing the spread of infection, healthcare system and
government majorly investing in new drug development and the traditional process of
drug discovery is very complex and lengthy. While the key value of
bio simulation comes from understanding clinical outcomes in discovery or
development well before any human trial occurs. This will be beneficial for the
vaccine manufacturers who are involved in developing vaccines against COVID-19,
by the time a vaccine is ready for mass production. Currently, as the entire
health care system is primarily focused on treating and developing vaccines for
this virus, the major bio simulation service providers across the globe will
experience significant growth during the 2020 COVID-19 outbreak. In addition,
the rising government funding in R&D to control and contain the virus is
also anticipated to drive the adoption of bio simulation in research facilities.
Increased healthcare spending, growing demand for advanced
therapeutics, and increased use of personalized medicines are the major driving
factors for the growth of bio simulation market. Rising demand for bio simulation
for finding various therapeutic approaches on different categories of people
and a better understanding of disease heterogeneity will increase the demand for
bio simulation. Factors such as increasing investments by the pharmaceutical and
biotechnology industries for technological innovations and the introduction of
modeling tools and advanced computer technologies are contributing to the
growth of the market. However, a lack of trained professionals may hamper the
bio simulation market growth. Furthermore, rising clinical requirements on the development of advanced drugs and growing focus on R&D activities will
offer lucrative opportunities for the growth of bio simulation in the near
future.
Geographically, North America held the largest share in
bio simulation market in 2019. The US is a key revenue generator in North
America bio simulation market. The factors such as an increase in investments in
new drug development and rising focus on partnership and M&A activities
will increase the demand for bio simulation software’s in this region. However, Asia
Pacific will witness a rapid growth in the market owing to the increasing demand for
technologically advanced software for drug discovery in the region. Moreover,
the growing healthcare infrastructure in Asian countries is expected to
escalate the demand for bio simulation over the forecast period.
Segment Covered
The report on global bio simulation market covers segments
such as product, application, and end-user. On the basis of product, the
sub-markets include software, and service. On the basis of application, the
sub-markets include preclinical testing, and clinical trials. On the basis of
end-user, the sub-markets include biotech, pharma companies, CROs, and
regulatory bodies.
Companies Profiled:
The report provides profiles of the companies in the market
such as Certara USA, Inc., Simulation Plus Inc., Dassault Systèmes SA,
Medtronic plc, Chemical Computing Group, Inc., Advanced Chemistry Development,
Inc., Entelos Holding Corporation, Genedata Ag, Physiomics PLC, and Rhenovia
Pharma Ltd..
Report Highlights:
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of bio simulation market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
